According to Persistence Market Research’s latest report, the Global Orally Disintegrating Tablet Market size will surpass US$ 27,222.9 Million in terms of market value by 2025, at a CAGR of 8.5%. Orally disintegrating tablets are becoming more popular among consumers and patients, owing to their uses in the treatment of illnesses affecting the central nervous system (CNS), gastrointestinal (GI), cardiovascular problems, and allergies.
Tablets and capsules have restrictions such as unpleasant taste, difficulty in swallowing, and large size, which are particularly problematic for elderly patients and children. These tablet and capsule constraints are important driving forces in the orally disintegrating tablet market. The convenience with which orally disintegrating tablets dissolve in saliva within a few seconds and the precision of dosing when compared to liquid forms and chewable tablets are expected to promote ODT adoption and drive the market expansion of the Orally Disintegrating Tablet Market.
Get Free Sample Copy of this Report@ https://www.persistencemarketresearch.com/samples/14572
Furthermore, the fact that Orally Disintegrating Tablets are increasingly being adopted as an alternative to traditional tablets or capsules due to improved Drug Bioavailability is projected to drive market growth over the forecast period. Apart from that, increased expenditure in clinical trials and clinical research to develop higher-quality orally disintegrating tablets is anticipated to drive the market in the near future.
Companies
- Teva Pharmaceutical Industries Ltd.
- Novartis AG
- AstraZeneca
- Mylan N.V.
- Pfizer Inc.
- Johnson & Johnson Services, Inc.
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Bausch Health
- GlaxoSmithKline plc.
- Sun Pharmaceutical Industries Ltd.
- Bayer AG
- Eli Lily and Company
- Dr. Reddy’s Laboratories Ltd.
- Takeda Pharmaceutical Company Limited
Request for Methodology@ https://www.persistencemarketresearch.com/methodology/14572
North America to Hold Lion’s Share in the Market
According to PMR’s regional analysis, North America is likely to have a large market share throughout the forecast period due to the increasing adoption of technologically improved goods and the rising incidence of CNS illnesses. Apart from this, due to the low cost of orally disintegrating tablets and increased awareness of various tablet dosage forms, the Asia Pacific and the Middle East, and Africa are also anticipated to grow significantly over the forecast period.
Access Full Report@ https://www.persistencemarketresearch.com/checkout/14572
Want More Insights?
PMR has presented a comprehensive report based on Orally Disintegrating Tablet Market as per Drug Class (Anti-Psychotics, Anti-Epileptics, CNS Stimulants, Anxiolytics, Anti-Parkinsonian Drugs, Anti-Hypertensives, NSAIDS, Anti-Allergy Drugs, Proton Pump Inhibitors, Others), Disease Indication (CNS Diseases, GI Diseases, CVS Disorders, Allergy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Drug Stores, Online Pharmacies) based on seven regions.
About Us: Persistence Market Research
Contact Us:
Persistence Market Research
Address – 305 Broadway, 7th Floor, New York City, NY 10007 United States
U.S. Ph. – +1-646-568-7751
USA-Canada Toll-free – +1 800-961-0353
Sales – sales@persistencemarketresearch.com